Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults
Completed · Phase 1 · NCT05935917
Conditions: Smallpox
At a glance
- Research payments reported, 2025
- $97,904
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 44
About the trial
- Sponsor
- Emergent BioSolutions
- Tested
- Brincidofovir (drug)
- Dates
- Started 2023-05-30; completion 2023-09-27
- Results posted
- Not yet
The goal of this clinical trial is to evaluate whether both Form H and Form II, 100mg brincidofovir tablets are bioequivalent, when given under fasting conditions in healthy adults. Participants will be randomized to each receive one tablet of Form H and one tablet of Form II,14 days apart and undergo pharmacokinetic testing pre-dose and post-dose to evaluate safety. This is an open-label, single-dose, randomized, two-period, crossover study.
From ClinicalTrials.gov, last updated 2025-01-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Emergent Biosolutions Inc. reported $97,904 in research payments for this study in 2025 (9 payments).
Products named: Tembexa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $97,904
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.